Isavuconazole for the Treatment of Fungal Infections: A Real-life Experience From the Fungal Infection Network of Switzerland (FUNGINOS).
aspergillosis
hepatotoxicity
liver
mucormycosis
triazoles
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
May 2024
May 2024
Historique:
received:
08
03
2024
accepted:
24
04
2024
medline:
17
5
2024
pubmed:
17
5
2024
entrez:
17
5
2024
Statut:
epublish
Résumé
This analysis of 116 isavuconazole therapy courses shows that hepatic test disturbances (HTDs) were relatively frequent (29% of cases) but rarely led to treatment interruption (5%). Importantly, patients with baseline HTDs, including those attributed to a first-line triazole, did not exhibit a higher risk of subsequent HTD under isavuconazole therapy.
Identifiants
pubmed: 38756765
doi: 10.1093/ofid/ofae223
pii: ofae223
pmc: PMC11097116
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofae223Investigateurs
Werner Albrich
(W)
Sabina Berezowska
(S)
Christoph Berger
(C)
Anne Bergeron
(A)
Pierre-Yves Bochud
(PY)
Katia Boggian
(K)
Anna Conen
(A)
Stéphane Emonet
(S)
Véronique Erard
(V)
Christian Garzoni
(C)
Daniel Goldenberger
(D)
Vladimira Hinic
(V)
Cedric Hirzel
(C)
Nina Khanna
(N)
Malte Kohns
(M)
Andreas Kronenberg
(A)
Frederic Lamoth
(F)
Basile Landis
(B)
Oscar Marchetti
(O)
Konrad Mühlethaler
(K)
Linda Müller
(L)
Dionysios Neofytos
(D)
Michael Osthoff
(M)
Jean-Luc Pagani
(JL)
Chantal Quiblier
(C)
Ilana Reinhold
(I)
Arnaud Riat
(A)
Niels Rupp
(N)
Dominique Sanglard
(D)
Peter Werner Schreiber
(PW)
Martin Siegemund
(M)
Laura Walti
(L)
Informations de copyright
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Déclaration de conflit d'intérêts
Potential conflicts of interest. Outside the submitted work: F. L. received research funding from Gilead, MSD, and Novartis and speaker honoraria from Pfizer, Gilead, MSD, Mundipharma, and Becton-Dickinson. All contracts were made with and fees paid to his institution. P. W. S. received travel grants from Pfizer and Gilead, speaker honorary from Pfizer, and fees for advisory board activity from Pfizer and Gilead. All other authors report no potential conflicts.